Potential Sciences
Potential Sciences is a London-based AI drug-discovery startup founded in 2025.
Position in SVTRnew
Snapshot 2026-11-07- Startup SignalsRankedof 2,355
- Life SciencesRankedof 252
- AI for ScienceRankedof 117
- Drug DiscoveryRankedof 73
About
Potential Sciences is a London-based AI drug-discovery startup founded in 2025. It trains AI models on GPU-native quantum-chemistry simulations and computer-generated biochemical data instead of relying on wet-lab results, so that weak drug candidates fail fast and discovery costs fall.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 3
Founders / team· 1
Funding history
- 2026-11-06Seed
Investors · Twin Path Ventures, Patrick Collison, Sovereign AISource · wired.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Potential Sciences
Potential Sciences is a London-based AI drug-discovery startup founded in 2025.
Seed · 2026-11
—
United States
BusinessLatest roundTotal raisedDate- Valo Health
Computational drug discovery/development platform built on AI and human data…
Series B · $450M · 2021-01
$450M - Synfini
AI- and robotic automation-driven platform to accelerate small-molecule drug discovery and chemical synthesis
$53M
$53M - Onepot
Small-molecule synthesis for drug discovery for biopharma companies (AI + automated synthesis)
Seed · $13M · 2025-11
$13M
China
BusinessLatest roundTotal raisedDate- Coherence Biotech Co. Ltd.
Lab automation: the Keystone™ benchtop all-in-one system combines culturing…
— - Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B - NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders…
Series B · 2026-09
—
Europe
BusinessLatest roundTotal raisedDate- Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M - Vitroscope
Ex vivo perfusion culture systems for living human tissue (vitro.alive / vitro.scale) that generate longitudinal biological data for drug discovery
Seed · $9M · 2026-11
$9M
Other / unspecified
BusinessLatest roundTotal raisedDate- Venomics AI
Drug discovery platform combining AI and venom biology to screen and develop drug candidates from animal venoms
Pre-Seed · $3M · 2026-11
$3M - Miles Wang 新公司
Develops AI models for drug discovery
— - Astellas Pharma
Research, manufacturing and sale of prescription drugs in oncology, ophthalmology, urology, immunology and women's health.
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Y Combinator
39 Life Sciences deals in the last 24 months · 27 at a nearby stage · 3 in Western Europe
Request intro →General Catalyst
38 Life Sciences deals in the last 24 months · 17 at a nearby stage · 1 in Western Europe
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 3 at a nearby stage · 3 in Western Europe
Request intro →Alumni Ventures
12 Life Sciences deals in the last 24 months · 8 at a nearby stage · 1 in Western Europe
Request intro →Accel
12 Life Sciences deals in the last 24 months · 8 at a nearby stage · 3 in Western Europe
Request intro →GV
12 Life Sciences deals in the last 24 months · 3 at a nearby stage · 3 in Western Europe
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.